1
|
Vyas VK, Parikh P, Ramani J, Ghate M. Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017). Curr Med Chem 2019; 26:2062-2084. [PMID: 29714134 DOI: 10.2174/0929867325666180430152023] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 12/22/2017] [Accepted: 04/25/2018] [Indexed: 11/22/2022]
Abstract
BACKGROUND Potassium (K+) channels participate in many physiological processes, cardiac function, cell proliferation, neuronal signaling, muscle contractility, immune function, hormone secretion, osmotic pressure, changes in gene expression, and are involved in critical biological functions, and in a variety of diseases. Potassium channels represent a large family of tetrameric membrane proteins. Potassium channels activation reduces excitability, whereas channel inhibition increases excitability. OBJECTIVE Small molecule K+ channel activators and inhibitors interact with voltage-gated, inward rectifying, and two-pore tandem potassium channels. Due to their involvement in biological functions, and in a variety of diseases, small molecules as potassium channel modulators have received great scientific attention. METHODS In this review, we have compiled the literature, patents and patent applications (2011 to 2017) related to different chemical classes of potassium channel openers and blockers as therapeutic agents for the treatment of various diseases. Many different chemical classes of selective small molecule have emerged as potassium channel modulators over the past years. CONCLUSION This review discussed the current understanding of medicinal chemistry research in the field of potassium channel modulators to update the key advances in this field.
Collapse
Affiliation(s)
- Vivek K Vyas
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382 481 Gujarat, India
| | - Palak Parikh
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382 481 Gujarat, India
| | - Jonali Ramani
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382 481 Gujarat, India
| | - Manjunath Ghate
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382 481 Gujarat, India
| |
Collapse
|
2
|
Abe T, Itoh T, Terasaki M. Total Synthesis of Fontanesine B and Its Isomer: Their Antiproliferative Activity against Human Colorectal Cancer Cells. Helv Chim Acta 2019. [DOI: 10.1002/hlca.201900116] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Takumi Abe
- Faculty of Pharmaceutical SciencesHealth Sciences University of Hokkaido, Ishikari-Tobetsu Hokkaido 061-0293 Japan
| | - Tomoki Itoh
- Faculty of Pharmaceutical SciencesHealth Sciences University of Hokkaido, Ishikari-Tobetsu Hokkaido 061-0293 Japan
| | - Masaru Terasaki
- Faculty of Pharmaceutical SciencesHealth Sciences University of Hokkaido, Ishikari-Tobetsu Hokkaido 061-0293 Japan
| |
Collapse
|
3
|
Pirotte B, Florence X, Goffin E, Lebrun P. 2,2-Dimethyl-3,4-dihydro-2 H-1,4-benzoxazines as isosteres of 2,2-dimethylchromans acting as inhibitors of insulin release and vascular smooth muscle relaxants. MEDCHEMCOMM 2019; 10:431-438. [PMID: 31015906 DOI: 10.1039/c8md00593a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 02/01/2019] [Indexed: 11/21/2022]
Abstract
The present study describes the synthesis and biological evaluation of 4-phenylureido/thioureido-substituted 2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of corresponding 2,2-dimethylchromans reported to be pancreatic β-cell KATP channel openers. The benzoxazines were found to be less active as inhibitors of the glucose-induced insulin release than their corresponding chromans, while the myorelaxant activity of some 4-arylureido-substituted benzoxazines was more pronounced than that exhibited by their chroman counterparts. The myorelaxant activity of the most potent benzoxazine 8e was further characterized on rat aortic rings precontracted by 30 mM KCl in the presence of glibenclamide (10 μM) or precontracted by 80 mM extracellular KCl. Our findings indicate that, on vascular smooth muscle cells, the benzoxazine 8e mainly behaved as a calcium entry blocker.
Collapse
Affiliation(s)
- Bernard Pirotte
- Laboratoire de Chimie Pharmaceutique , Center for Interdisciplinary Research on Medicines (CIRM) , Université de Liège , Quartier Hôpital , Avenue Hippocrate 15 , B-4000 Liège , Belgium .
| | - Xavier Florence
- Laboratoire de Chimie Pharmaceutique , Center for Interdisciplinary Research on Medicines (CIRM) , Université de Liège , Quartier Hôpital , Avenue Hippocrate 15 , B-4000 Liège , Belgium . .,Laboratoire de Physiologie et Pharmacologie , Université Libre de Bruxelles , Faculté de Médecine , 808 Route de Lennik , B-1070 Bruxelles , Belgium
| | - Eric Goffin
- Laboratoire de Chimie Pharmaceutique , Center for Interdisciplinary Research on Medicines (CIRM) , Université de Liège , Quartier Hôpital , Avenue Hippocrate 15 , B-4000 Liège , Belgium .
| | - Philippe Lebrun
- Laboratoire de Physiologie et Pharmacologie , Université Libre de Bruxelles , Faculté de Médecine , 808 Route de Lennik , B-1070 Bruxelles , Belgium
| |
Collapse
|
4
|
Bouhedja M, Peres B, Fhayli W, Ghandour Z, Boumendjel A, Faury G, Khelili S. Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis. Eur J Med Chem 2018; 144:774-796. [DOI: 10.1016/j.ejmech.2017.12.071] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 12/17/2017] [Accepted: 12/18/2017] [Indexed: 11/27/2022]
|
5
|
Pirotte B, Florence X, Goffin E, Lebrun P. Deciphering Structure-Activity Relationships in a Series of 2,2-Dimethylchromans Acting as Inhibitors of Insulin Release and Smooth Muscle Relaxants. ChemMedChem 2017; 12:1810-1817. [DOI: 10.1002/cmdc.201700409] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 09/20/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Bernard Pirotte
- Laboratoire de Chimie Pharmaceutique; Center for Interdisciplinary Research on Medicines (CIRM); Université de Liège; Quartier Hôpital, Avenue Hippocrate 15 4000 Liège Belgium
| | - Xavier Florence
- Laboratoire de Chimie Pharmaceutique; Center for Interdisciplinary Research on Medicines (CIRM); Université de Liège; Quartier Hôpital, Avenue Hippocrate 15 4000 Liège Belgium
- Laboratoire de Physiologie et Pharmacologie; Université Libre de Bruxelles; Faculté de Médecine; 808 Route de Lennik 1070 Bruxelles Belgium
| | - Eric Goffin
- Laboratoire de Chimie Pharmaceutique; Center for Interdisciplinary Research on Medicines (CIRM); Université de Liège; Quartier Hôpital, Avenue Hippocrate 15 4000 Liège Belgium
| | - Philippe Lebrun
- Laboratoire de Physiologie et Pharmacologie; Université Libre de Bruxelles; Faculté de Médecine; 808 Route de Lennik 1070 Bruxelles Belgium
| |
Collapse
|
6
|
Schnekenburger M, Goffin E, Lee JY, Jang JY, Mazumder A, Ji S, Rogister B, Bouider N, Lefranc F, Miklos W, Mathieu V, de Tullio P, Kim KW, Dicato M, Berger W, Han BW, Kiss R, Pirotte B, Diederich M. Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. J Med Chem 2017; 60:4714-4733. [PMID: 28475330 DOI: 10.1021/acs.jmedchem.7b00533] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
A new series of N-aryl-N'-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)ureas bearing an alkoxycarbonylamino group at the 6-position were synthesized and examined as putative anticancer agents targeting sirtuins in glioma cells. On the basis of computational docking combined to in vitro sirtuin 1/2 inhibition assays, we selected compound 18 [R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea] which displays a potent antiproliferative activity on various glioma cell types, assessed by quantitative videomicroscopy, eventually triggering senescence. The impact on normal glial cells was lower with a selectivity index of >10. Furthermore, human U373 and Hs683 glioblastoma cell lines served to demonstrate the inhibitory activity of 18 against histone deacetylase (HDAC) class III sirtuins 1 and 2 (SIRT1/2) by quantifying acetylation levels of histone and non-histone proteins. The translational potential of 18 was validated by an NCI-60 cell line screen and validation of growth inhibition of drug resistant cancer cell models. Eventually, the anticancer potential of 18 was validated in 3D glioblastoma spheroids and in vivo by zebrafish xenografts. In summary, compound 18 is the first representative of a new class of SIRT inhibitors opening new perspectives in the medicinal chemistry of HDAC inhibitors.
Collapse
Affiliation(s)
- Michael Schnekenburger
- Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg , 9, Rue Edward Steichen, L-2540 Luxembourg, Luxembourg
| | - Eric Goffin
- Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège , 4000 Liège, Belgium
| | - Jin-Young Lee
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| | - Jun Young Jang
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| | - Aloran Mazumder
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| | - Seungwon Ji
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| | - Bernard Rogister
- Nervous System Diseases and Treatment, GIGA-Neurosciences, University of Liège , 4000 Liège, Belgium
| | - Nafila Bouider
- Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège , 4000 Liège, Belgium
| | - Florence Lefranc
- Service de Neurochirurgie, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Walter Miklos
- Department of Medicine I, Comprehensive Cancer Center and Institute of Cancer Research, Medical University of Vienna , 1090 Vienna, Austria
| | - Véronique Mathieu
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles , 1050 Brussels, Belgium
| | - Pascal de Tullio
- Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège , 4000 Liège, Belgium
| | - Kyu-Won Kim
- SNU-Harvard Neurovascular Protection Center, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University , Seoul 151-742, Korea
| | - Mario Dicato
- Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg , 9, Rue Edward Steichen, L-2540 Luxembourg, Luxembourg
| | - Walter Berger
- Department of Medicine I, Comprehensive Cancer Center and Institute of Cancer Research, Medical University of Vienna , 1090 Vienna, Austria
| | - Byung Woo Han
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles , 1050 Brussels, Belgium
| | - Bernard Pirotte
- Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège , 4000 Liège, Belgium
| | - Marc Diederich
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University , 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea
| |
Collapse
|
7
|
Efficient synthesis and biological evaluation of new benzopyran-annulated pyrano[2,3-c]pyrazole derivatives. Mol Divers 2017; 21:339-354. [DOI: 10.1007/s11030-017-9734-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 02/20/2017] [Indexed: 12/27/2022]
|
8
|
Pirotte B, Florence X, Goffin E, Medeiros MB, de Tullio P, Lebrun P. 4-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky ‘carbamate’ moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion. Eur J Med Chem 2016; 121:338-351. [DOI: 10.1016/j.ejmech.2016.05.042] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 05/19/2016] [Accepted: 05/20/2016] [Indexed: 11/25/2022]
|
9
|
Florence X, Desvaux V, Goffin E, de Tullio P, Pirotte B, Lebrun P. Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers? Eur J Med Chem 2014; 80:36-46. [PMID: 24763361 DOI: 10.1016/j.ejmech.2014.04.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 03/28/2014] [Accepted: 04/05/2014] [Indexed: 10/25/2022]
Abstract
The present study described the synthesis of original R/S-6-alkylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans bearing a 3- or 4-substituted phenylthiourea or phenylurea moiety at the 4-position. Their biological effects were evaluated both on insulin-secreting and smooth muscle cells and were compared to those of reference KATP channel activators such as (±)-cromakalim, diazoxide and previously synthesized cromakalim analogues. The study aimed at exploring the influence of the introduction of an alkylsulfonylamino substituent at the 6-position of 2,2-dimethylchromans in order to improve biological activity, tissue selectivity but also hydrophilicity of dihydrobenzopyran derivatives. Several compounds were found to be equipotent or even more potent than (±)-cromakalim and diazoxide at inhibiting the insulin releasing process. Most of the newly synthesized and more hydrophilic dihydrobenzopyrans also exhibited a marked vasorelaxant activity although they were less potent than (±)-cromakalim. Additional pharmacological and radioisotopic investigations suggested that R/S-N-3-chlorophenyl-N'-(3,4-dihydro-6-methylsulfonylamino-2,2-dimethyl-2H-1-benzopyran-4-yl)thiourea (21) did not act as a potassium channel opener but rather as a Ca(2+) entry blocker.
Collapse
Affiliation(s)
- Xavier Florence
- Laboratoire de Pharmacodynamie et de Thérapeutique, Université Libre de Bruxelles, Faculté de Médecine, 808 Route de Lennik, B-1070 Bruxelles, Belgium.
| | - Vincent Desvaux
- Centre de Recherches du Cyclotron, Université de Liège, 8 Allée du 6 Août, B-4000 Liège, Belgium
| | - Eric Goffin
- Laboratoire de Chimie Pharmaceutique, Centre Interfacultaire de Recherche du Médicament (C.I.R.M.), Université de Liège, C.H.U., 1 Avenue de l'Hôpital, B-4000 Liège, Belgium
| | - Pascal de Tullio
- Laboratoire de Chimie Pharmaceutique, Centre Interfacultaire de Recherche du Médicament (C.I.R.M.), Université de Liège, C.H.U., 1 Avenue de l'Hôpital, B-4000 Liège, Belgium
| | - Bernard Pirotte
- Laboratoire de Chimie Pharmaceutique, Centre Interfacultaire de Recherche du Médicament (C.I.R.M.), Université de Liège, C.H.U., 1 Avenue de l'Hôpital, B-4000 Liège, Belgium
| | - Philippe Lebrun
- Laboratoire de Pharmacodynamie et de Thérapeutique, Université Libre de Bruxelles, Faculté de Médecine, 808 Route de Lennik, B-1070 Bruxelles, Belgium
| |
Collapse
|
10
|
Raphemot R, Swale DR, Dadi PK, Jacobson DA, Cooper P, Wojtovich AP, Banerjee S, Nichols CG, Denton JS. Direct activation of β-cell KATP channels with a novel xanthine derivative. Mol Pharmacol 2014; 85:858-65. [PMID: 24646456 DOI: 10.1124/mol.114.091884] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
ATP-regulated potassium (KATP) channel complexes of inward rectifier potassium channel (Kir) 6.2 and sulfonylurea receptor (SUR) 1 critically regulate pancreatic islet β-cell membrane potential, calcium influx, and insulin secretion, and consequently, represent important drug targets for metabolic disorders of glucose homeostasis. The KATP channel opener diazoxide is used clinically to treat intractable hypoglycemia caused by excessive insulin secretion, but its use is limited by off-target effects due to lack of potency and selectivity. Some progress has been made in developing improved Kir6.2/SUR1 agonists from existing chemical scaffolds and compound screening, but there are surprisingly few distinct chemotypes that are specific for SUR1-containing KATP channels. Here we report the serendipitous discovery in a high-throughput screen of a novel activator of Kir6.2/SUR1: VU0071063 [7-(4-(tert-butyl)benzyl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione]. The xanthine derivative rapidly and dose-dependently activates Kir6.2/SUR1 with a half-effective concentration (EC50) of approximately 7 μM, is more efficacious than diazoxide at low micromolar concentrations, directly activates the channel in excised membrane patches, and is selective for SUR1- over SUR2A-containing Kir6.1 or Kir6.2 channels, as well as Kir2.1, Kir2.2, Kir2.3, Kir3.1/3.2, and voltage-gated potassium channel 2.1. Finally, we show that VU0071063 activates native Kir6.2/SUR1 channels, thereby inhibiting glucose-stimulated calcium entry in isolated mouse pancreatic β cells. VU0071063 represents a novel tool/compound for investigating β-cell physiology, KATP channel gating, and a new chemical scaffold for developing improved activators with medicinal chemistry.
Collapse
Affiliation(s)
- Rene Raphemot
- Departments of Anesthesiology (R.R., D.R.S., S.B., J.S.D.), Pharmacology (R.R., J.S.D.), and Molecular Physiology and Biophysics (P.K.D., D.A.J.) and Institutes of Chemical Biology (J.S.D.) and Global Health (J.S.D.), Vanderbilt University Medical Center, Nashville, Tennessee; Department of Medicine, University of Rochester Medical Center, Rochester, New York (A.P.W.); and Department of Cell Biology and Physiology (P.C., C.G.N.) and Center for the Investigation of Membrane Excitability Disorders (P.C., C.G.N.), Washington University School of Medicine in St. Louis, St. Louis, Missouri
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Constant-Urban C, Charif M, Goffin E, Van Heugen JC, Elmoualij B, Chiap P, Mouithys-Mickalad A, Serteyn D, Lebrun P, Pirotte B, De Tullio P. Triphenylphosphonium salts of 1,2,4-benzothiadiazine 1,1-dioxides related to diazoxide targeting mitochondrial ATP-sensitive potassium channels. Bioorg Med Chem Lett 2013; 23:5878-81. [DOI: 10.1016/j.bmcl.2013.08.091] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2013] [Revised: 08/22/2013] [Accepted: 08/26/2013] [Indexed: 01/03/2023]
|